Biography

Menassie M. Taddese is a biopharmaceutical executive with nearly 30 years of global leadership experience spanning commercial operations, corporate finance, business transformation, and corporate governance. He most recently served as President, Emerging Markets at Viatris, where he led an approximately $3 billion business operating across more than 125 markets, spanning four major therapeutic areas, and employing approximately 3,500 people. During his tenure, he led the integration of the Mylan and Upjohn businesses, exceeded projected financial performance, and expanded operating margins.

Previously, Taddese spent more than 20 years at Pfizer in roles spanning corporate finance, treasury, commercial leadership, and general management. He was one of the founding leaders of Pfizer's Upjohn business and served as Vice President and Chief Financial Officer of Pfizer's Global Innovative Pharma Segment North America, an approximately $8 billion business.

In addition to his executive leadership experience, Taddese brings significant board and financial oversight expertise. He serves as an independent director and Chair of the Audit Committee at Medexus Pharmaceuticals (TSX: MDP). His other board and advisory roles include the Business Council for International Understanding, the American School of Dubai and One Acre Fund. He is also a Senior Advisor at EMIR Group.

Taddese holds an MBA in Finance with distinction from Penn State Smeal College of Business and completed an Executive Program in Management at Columbia Business School. His professional honors include the Pharmaceutical Executive Emerging Leader Award and the Penn State Smeal College of Business Distinguished Achievement Award.

Committee Roles:
Member of the Audit Committee